Susceptibility testing
MICs were determined by a standard two-fold agar dilution technique as recommended by the Japan Society of Chemotherapy. 7 Sensitivity test agar (STA; Eiken Chemical Co., Ltd, Tokyo, Japan) was used as the test medium for staphylococci, enterococci and Gram-negative enteric bacteria; STA supplemented with 10% defibrinated horse blood was used for streptococci; STA supplemented with 5% Fildes' enrichment (Difco Laboratories, Detroit, MI, USA) was used for Haemophilus influenzae; chocolate STA was used for Moraxella catarrhalis; chocolate GC medium base (Difco) was used for Neisseria spp.; GAM agar (Nissui Seiyaku Co., Ltd, Tokyo, Japan) was used for obligate anaerobic bacteria; and brain heart infusion agar (Difco) supplemented with 0.1% -cyclodextrin (Nihon Shokuhin Kako Co., Ltd, Tokyo, Japan) for supporting flourishing growth was used for Helicobacter pylori. The final inoculum size was 5 10 3 cfu/spot (5 L). The inoculated plates were incubated at 37°C for 18 h, except for Neisseria spp. (which were incubated in a candle jar for 48 h) and H. pylori (which were incubated in a microaerophilic atmosphere of 5% O 2 , 10% CO 2 and 85% N 2 for 72 h). Obligate anaerobic bacteria were incubated in an anaerobic chamber (Forma Scientific, Marietta, OH, USA).
Effects of various conditions on antibacterial activity
The effects of various factors on the antibacterial activities of R-95867, cefpodoxime, cefdinir, imipenem and oflo x a c i n were determined with one isolate each
of S t a p h y l o c o c c u s a u r e u s, Enterococcus faecalis, Escherichia coli, K l e b s i e l l a p n e u m o n i a e and Enterobacter cloacae.
The effect of pH on the MICs was determined with STA adjusted to pH 5.5, 7.0 or 8. 5 . The effect of serum on the MICs was determined with STA supplemented with heat-inactivated horse serum to final concentrations of 10, 25 and 50%. The effect of inoculum size on the MICs was determined by inoculating 5 1 0 2 -5 1 0 5 cfu/spot on to STA plates.
Killing-curve tests
The bactericidal activity of R-95867 was determined using one isolate each of S. aureus and E. coli. An overnight culture in tryptone-soya broth (TSB; Nissui) was diluted with fresh TSB and incubated at 37°C, with shaking, to yield approximately 10 6 cfu/mL; then R-95867 was added to a final concentration of 0.25-4 MIC. The MICs were determined by a two-fold broth dilution technique using TSB as the test medium. 8 After incubation for 1, 2 or 4 h at 37°C, with shaking, a sample was withdrawn and serially diluted with saline. One hundred microlitres of the diluent was mixed with 10 mL of molten heart infusion agar (HIA; Nissui) and incubated at 37°C for 24 h, to count the cfu/mL. Drug carryover did not affect colony formation, since samples were diluted 100-fold with HIA. Colonies were counted on plates yielding 30-300 colonies. The lower limit of sensitivity of colony counts was 300 cfu/mL.
Differential interference microscopy
For the morphological alteration study, E. coli K-12 was cultivated on STA containing various concentrations of R-95867 on a glass slide, and the plates were observed after 3 h of incubation by differential interference microscopy (Optiphoto XF-NT, Nikon, Tokyo, Japan).
Assay of PBPs
The affinities of R-95867 and cefdinir for PBPs of E. coli K-12 were determined by the method reported by Spratt. The concentration of each drug that inhibited the subsequent binding of [ 14 C]benzylpenicillin (Amersham Japan, Tokyo, Japan) to each PBP by 50% (IC 50 ) was determined by scanning the fluorograms with an imaging densitometer (Model GS-670, Bio-Rad, Hercules, CA, USA).
Systemic infections in mice
Male ddY mice weighing about 18 g (SLC Japan Inc., Shizuoka, Japan) were infected intraperitoneally with 0.5 mL of bacterial suspension. The strains and the challenge dose per mouse were as follows: S. 3 cfu. S. pneumoniae and S. pyogenes were injected as suspensions in heart infusion broth (Nissui). The other organisms were injected as suspensions in 5% gastric mucin (Wako Chemicals, Osaka, Japan). CS-834, cefpodoxime proxetil, cefdinir, cefditoren pivoxil and levofloxacin were administered orally in a volume of 0.2 mL of 0.5% carboxymethyl cellulose sodium salt (Wako Chemicals) 2 h after infection. Serial two-fold doses of the test drugs were employed, using ten mice at each dose. Results were expressed as the 50% effective dose (ED 50 ) and 95% confidence limits by the probit method from the survival rates on day 7 after challenge. 10 Animal experiments were carried out according to the guidelines provided by the Institutional Animal Care and Use Committee of Kyoto Pharmaceutical University, Kyoto, Japan.
Results

Antibacterial activity
The antibacterial activities of R-95867, cefpodoxime, cefdinir, cefditoren, imipenem and ofloxacin were determined for 807 clinical isolates. Table I faecium, the MIC 90 s of R-95867 were 12.5 and 50 mg/L, respectively. This activity was greater than those of the cephems, but it was four to eight times lower than those of imipenem and ofloxacin. R-956867 was inactive against Enterococcus avium (MIC 90 100 mg/L), as were the reference -lactams. Against Neisseria gonorrhoeae, the activity of R-95867 was comparable to that of cefdinir and ofloxacin, and it was four times that of cefpodoxime, cefditoren and imipenem. The MIC 90 s of R-95967 for E. coli, Citrobacter freundii, K. pneumoniae, Proteus vulgaris and Proteus mirabilis were 0.05-1.56 mg/L. It was the most active of all the compounds tested. The activity of R-95867 against Enterobacter aerogenes, Morganella morganii, Providencia rettgeri, Acinetobacter calcoaceticus and M. catarrhalis was comparable to or greater than that of the reference compounds. Against E. cloacae, the activity of R-95867 was comparable to or greater than that of cephems and imipenem, and lower than that of ofloxacin. R-95867 was more active against Serratia marcescens than were the cephems and ofloxacin, but four times less active than imipenem. The MIC 90 of R95867 against P. aeruginosa was 50 mg/L. Its activity was greater than that of the cephems and ofloxacin, but it was eight times lower than that of imipenem. Against H. influenzae, R-95867 was as active as cefpodoxime and ofloxacin, and four to 32 times more active than cefdinir and imipenem, but four times less active than cefditoren.
The antibacterial activities of R-95867, amoxycillin, clarithromycin and lansoprazole (a proton-pump inhibitor that increases gastric pH) were determined for 36 clinical isolates of H. pylori. Against H. pylori, R-95867 was more active than amoxycillin and lansoprazole and similar to clarithromycin. Table II shows the antibacterial activities of R-95867, cefpodoxime, cefdinir, cefditoren, imipenem and ofloxacin against obligatory anaerobes and Salmonella spp., Shigella spp. and Neisseria meningitidis. The antibacterial activity of R-95867 against obligatory anaerobes was comparable to or greater than those of the reference compounds. R-95867 inhibited Salmonella spp. and Shigella spp. at concentrations 0.10 mg/L. The antibacterial activity of R-95867 against these species was comparable to or greater than that of the reference compounds. R-95867 showed the greatest activity against N. meningitidis.
Effects of various conditions on antibacterial activity
Varying the pH of STA between 5.5 and 8.5 had no significant effect on the activity of R-95867 against each strain (Table III) . However, the activity of ofloxacin in STA at pH 5.5 was four to 32 times lower than that at pH 7.0. Addition of 10, 25 and 50% horse serum to STA, or increasing the inoculum size from 5 10 2 to 5 10 5 cfu/spot, had no significant effect on the activity of R-95867 against each strain (data not shown).
Bactericidal activity
The bactericidal activity of R-95867 was examined against S. aureus Smith and E. coli KC-14 ( Figure 2 ). The number of viable cells decreased rapidly during incubation with R-95867 at 1-4 MIC against S. aureus and at 0.5-4 MIC against E. coli.
Morphological effects
The morphological changes induced by R-95867 in E. coli K-12 were examined by differential interference microscopy (Figure 3) . No filamentous forms were observed, but R-95867 induced swelling at concentrations of 0.003 mg/L, and lysis at concentrations of 0.025 mg/L.
Binding affinity for PBPs
The binding affinities of R-95867 and cefdinir for PBPs of E. coli K-12 were determined. Table IV shows the results of fluorography by competition of R-95867 and cefdinir with [ 14 C]benzylpenicillin for PBPs. R-95867 had high affinity for PBPs 2, 3 and 4, and low affinities for PBPs 1Bs and 5/6. Cefdinir had high affinity for PBPs 1A, 1Bs and 3, and low affinities for PBPs 2 and 4. 
Efficacy against systemic infections in mice
The protective effect of CS-834 against systemic infections with S. aureus Smith, S. pneumoniae Type III, S. pyogenes C-203, E. coli KC-14 and K. pneumoniae KC-1 in mice were compared with those of cefpodoxime proxetil, cefdinir, cefditoren pivoxil and levofloxacin (Table V) . CS-834 showed the greatest efficacy of all the compounds tested against systemic infections caused by S. aureus and E. coli. The efficacy of CS-834 against Streptococcus spp. infections was better than that of levofloxacin, comparable to or less than that of cefpodoxime proxetil and cefditoren pivoxil, and comparable to or better than that of cefdinir. The efficacy of CS-834 against K. pneumoniae infection was better than that of cefdinir, comparable to that of cefditoren pivoxil, and less than those of cefpodoxime proxetil and levofloxacin.
Discussion
R-95867 showed broad-spectrum, potent antibacterial activity against Gram-positive and Gram-negative bacteria. It had high affinities for PBPs 2 and 3 of E. coli, which are reported to be involved in maintaining the shape of the bacterium and in septum formation, respectively. 1 1 Observation of morphological changes in E. coli under a differential interference contrast microscope revealed that swelling occurred at R-95867 concentrations of 0 . 0 0 3 mg/L, and lysis at concentrations of 0.025 mg/L. One of the most important features of R-95867 is its potent activity against S. pneumoniae, H. influ e n z a e and M. catarrhalis, which are major causes of pneumonia. Recently, penicillinresistant S. pneumoniae have been isolated all over the world, and the incidence of these strains has risen a l a r m i n g l y . 1 2 -1 4 S. pneumoniae strains that producelactamase have never been reported. Their resistance to -lactams is thought to result from alteration of their P B P s .
9 , 1 5 , 1 6
R-95867 showed strong activity against penicillin-susceptible and penicillin-resistant S. pneum o n i a e ( M I C 9 0 s of 0.05 and 0.39 mg/L, respectively), which was greater than that of cefpodoxime, cefdinir and o floxacin, and comparable to that of cefditoren and imipenem. The activity of R-95867 is probably less affected by alterations in PBPs of penicillin-resistant S. pneumoniae, because this compound shows stronger activity against these strains than the cephems tested. Against C. freundii and E n t e r o b a c t e r spp., R-95867 showed strong antibacterial activity (MIC 9 0 s 0.20-1.56 mg/L). Its activity was at least 32 times those of the cephems. One reason for this potent activity of R-95867 against those organisms is probably that R-95867 is highly stable against -lactamases produced by these organisms. 1 7 R-95867 showed potent activity against quinolone-resistant strains of S. aureus. Recent clinical isolates are often highly resistant to available quinolones, by various mechanisms, 1 8 -2 0 but R-95867 will be effective against those isolates.
435
Many reports indicate that gastric H. pylori infection is associated with chronic gastritis and peptic ulcer diseases. 21, 22 H. pylori eradication cures gastritis and markedly reduces the chance of ulcer relapse. 23 Amoxycillin, clarithromycin and lansoprazole are important components in the anti-H. pylori therapeutic regimen. 21 Amoxycillin and clarithromycin are administered orally, but it is unclear whether these antibiotics are active when they reach the stomach. Goddard et al. 24 reported that both amoxycillin and clarithromycin are found in human gastric juice after intravenous administration, so they may be secreted into the stomach. If this is the case, administration of CS-834 may also be effective in eradicating H. pylori. Further work is necessary to confirm this.
Against murine systemic infections caused by various Gram-positive and Gram-negative bacteria, CS-834 showed an excellent protective effect, because after oral administration to mice, it is well absorbed and rapidly distributed to various tissues. 25 Its in-vivo efficacy correlated well with the in-vitro activity of R-95867. CS-834 has been administered to humans and was shown to be well absorbed and rapidly transformed into an active metabolite, R-95867. 5 These results indicate that CS-834 would be a useful carbapenem for the treatment of various infections. Clinical studies on CS-834 are in progress in Japan and the USA. 
